|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
66,383,000 |
Market
Cap: |
1.42(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$16.53 - $28.72 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : 2 |
Insider 6 Months : 2 |
Insider 3/6 Months : 4.3 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Xencor is a clinical-stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. Co. is developing a portfolio of clinical-stage XmAb® drug candidates from its protein engineering technology platforms. Co.'s XmAb bispecific Fc drug candidates include: Vudalimab (XmAb717), which is a bispecific antibody that targets PD-1 and CTLA-4 and for patients with metastatic castration-resistant prostate cancer and other solid tumor types; and Plamotamab, which is a bispecific antibody that targets CD20, an antigen on B-cell tumors, and CD3, an activating receptor on T cells.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
53 |
53 |
53 |
53 |
Total Buy Value |
$1,013 |
$1,013 |
$1,013 |
$1,013 |
Total People Bought |
1 |
1 |
1 |
1 |
Total Buy Transactions |
1 |
1 |
1 |
1 |
Total Shares Sold |
106,096 |
151,096 |
184,593 |
219,438 |
Total Sell Value |
$2,264,335 |
$3,206,005 |
$4,083,291 |
$5,152,397 |
Total People Sold |
6 |
6 |
6 |
7 |
Total Sell Transactions |
11 |
12 |
13 |
28 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Ronin Capital, Llc |
10% Owner |
|
2017-08-22 |
4 |
B |
$19.67 |
$580,265 |
I/I |
29,500 |
5,215,551 |
1.5 |
- |
|
Ronin Capital, Llc |
10% Owner |
|
2017-08-21 |
4 |
B |
$19.74 |
$227,326 |
I/I |
11,516 |
5,186,051 |
1.5 |
- |
|
Ronin Capital, Llc |
10% Owner |
|
2017-08-18 |
4 |
B |
$19.93 |
$866,955 |
I/I |
43,500 |
5,174,535 |
1.5 |
- |
|
Ronin Capital, Llc |
10% Owner |
|
2017-08-17 |
4 |
B |
$20.47 |
$1,617,451 |
I/I |
79,035 |
5,131,035 |
1.5 |
- |
|
Ronin Capital, Llc |
10% Owner |
|
2017-08-16 |
4 |
B |
$20.96 |
$524,000 |
I/I |
25,000 |
5,052,000 |
1.5 |
- |
|
Ronin Capital, Llc |
10% Owner |
|
2017-08-11 |
4 |
B |
$21.05 |
$294,630 |
I/I |
14,000 |
5,027,000 |
1.5 |
- |
|
Ronin Capital, Llc |
10% Owner |
|
2017-08-10 |
4 |
B |
$21.22 |
$275,860 |
I/I |
13,000 |
5,013,000 |
1.5 |
- |
|
Ronin Capital, Llc |
10% Owner |
|
2017-06-28 |
4 |
B |
$19.94 |
$119,640 |
I/I |
6,000 |
5,000,000 |
1.5 |
- |
|
Ronin Capital, Llc |
10% Owner |
|
2017-06-16 |
4 |
B |
$19.67 |
$29,510 |
I/I |
1,500 |
4,994,000 |
1.5 |
- |
|
Carter Bruce L A |
Director |
|
2017-06-14 |
4 |
S |
$20.61 |
$412,238 |
D/D |
(20,000) |
48,578 |
|
- |
|
Carter Bruce L A |
Director |
|
2017-06-02 |
4 |
S |
$22.00 |
$52,052 |
D/D |
(2,366) |
68,578 |
|
- |
|
Carter Bruce L A |
Director |
|
2017-05-26 |
4 |
S |
$22.04 |
$275,213 |
D/D |
(12,400) |
70,944 |
|
- |
|
Carter Bruce L A |
Director |
|
2017-05-24 |
4 |
OE |
$0.59 |
$45,279 |
D/D |
76,744 |
83,344 |
|
- |
|
Baracchini Edgardo Jr |
Chief Business Officer |
|
2017-05-02 |
4 |
S |
$26.07 |
$19,551 |
D/D |
(750) |
0 |
|
- |
|
Baracchini Edgardo Jr |
Chief Business Officer |
|
2017-05-02 |
4 |
OE |
$0.59 |
$443 |
D/D |
750 |
750 |
|
- |
|
Baracchini Edgardo Jr |
Chief Business Officer |
|
2017-05-01 |
4 |
S |
$26.01 |
$255,366 |
D/D |
(9,818) |
0 |
|
- |
|
Baracchini Edgardo Jr |
Chief Business Officer |
|
2017-05-01 |
4 |
OE |
$0.59 |
$5,793 |
D/D |
9,818 |
9,818 |
|
- |
|
Baracchini Edgardo Jr |
Chief Business Officer |
|
2017-04-27 |
4 |
S |
$26.04 |
$23,540 |
D/D |
(904) |
0 |
|
- |
|
Baracchini Edgardo Jr |
Chief Business Officer |
|
2017-04-27 |
4 |
OE |
$0.59 |
$533 |
D/D |
904 |
904 |
|
- |
|
Kuch John J |
Vice President, Finance |
|
2017-03-16 |
4 |
S |
$24.42 |
$366,278 |
D/D |
(15,000) |
77,171 |
|
- |
|
Kuch John J |
Vice President, Finance |
|
2017-03-16 |
4 |
OE |
$0.59 |
$14,464 |
D/D |
24,516 |
92,171 |
|
- |
|
Desjarlais John R |
Sr. V.P., Research & CSO |
|
2017-03-16 |
4 |
GD |
$0.00 |
$0 |
D/D |
95 |
87,676 |
|
- |
|
Desjarlais John R |
Sr. V.P., Research & CSO |
|
2017-03-15 |
4 |
S |
$24.47 |
$336,637 |
D/D |
(13,755) |
87,771 |
|
- |
|
Ronin Capital, Llc |
10% Owner |
|
2016-12-06 |
4 |
S |
$27.71 |
$1,747,105 |
I/I |
(63,061) |
4,992,500 |
|
- |
|
Desjarlais John R |
Sr. V.P., Research & CSO |
|
2016-12-05 |
4 |
S |
$26.57 |
$1,195,515 |
D/D |
(45,000) |
101,381 |
|
- |
|
312 Records found
|
|
Page 8 of 13 |
|
|